PMID- 36469630
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230831
IS  - 1747-4132 (Electronic)
IS  - 1747-4124 (Linking)
VI  - 17
IP  - 8
DP  - 2023 Jul-Dec
TI  - An update on efficacy and safety comparison of biologics in treatment of 
      inflammatory bowel disease targeting TNF-alpha, interleukins, leukocyte trafficking, 
      Janus-kinase, and sphingosine-1-phosphate receptor.
PG  - 837-861
LID - 10.1080/17474124.2022.2155136 [doi]
AB  - INTRODUCTION: Along with the rising prevalence of inflammatory bowel disease 
      (IBD) [Crohn's disease (CD) and ulcerative colitis (UC)], biological therapies 
      need an update/insight. AREA COVERED: This review included randomized controlled 
      trials (RCTs) from PubMed database (2000-October 2022) of approved biologics and 
      small molecules with primary outcome analysis on efficacy (clinical 
      response/remission/mucosal healing) and/or adverse events (AEs). Considered for 
      this review under biologics classes are TNF-alpha inhibitors, leukocyte trafficking 
      inhibitors, and anti IL-12/IL-23; and under small molecules are Janus-kinase 
      inhibitors, and sphingosine-1-phosphate receptor modulators. EXPERT OPINION: In 
      CD, clinical response and remission were better with tofacitinib (61.23%) and 
      infliximab (44.86%), respectively, in the induction phase, and these were better 
      with ustekinumab in the maintenance phase. In UC, the maximum rate of response, 
      remission, and mucosal healing were obtained with infliximab during the induction 
      phase (67.49%, 35.99%, and 60.25%, respectively). During the maintenance phase, 
      response rate was better with ustekinumab, but remission and mucosal healing were 
      better with vedolizumab. The combined percentage of AEs was highest with 
      infliximab (174.45%) and least with ozanimod (23.04%), and most commonly belonged 
      to the 'infection and infestation system organ class (SOC).' These efficacy and 
      safety analyses will help in the optimization of biologic treatment in IBD.
FAU - Sarangi, Sudhir Chandra
AU  - Sarangi SC
AD  - Department of Pharmacology, All India Institute of Medical Sciences, New Delhi, 
      India.
FAU - Pattnaik, Soumya S
AU  - Pattnaik SS
AD  - Department of Pharmacology, All India Institute of Medical Sciences, New Delhi, 
      India.
FAU - Sinha, Surabhi
AU  - Sinha S
AD  - Department of Pharmacology, All India Institute of Medical Sciences, New Delhi, 
      India.
FAU - R, Govindaraj
AU  - R G
AD  - Department of Radiodiagnosis, NEIGRIHMS, Shilong, India.
LA  - eng
PT  - Journal Article
DEP - 20221226
PL  - England
TA  - Expert Rev Gastroenterol Hepatol
JT  - Expert review of gastroenterology & hepatology
JID - 101278199
SB  - IM
OTO - NOTNLM
OT  - Adverse events
OT  - Crohn's disease
OT  - biologics
OT  - clinical response
OT  - randomized controlled trials
OT  - ulcerative colitis
EDAT- 2022/12/06 06:00
MHDA- 2022/12/06 06:01
CRDT- 2022/12/05 14:12
PHST- 2022/12/06 06:01 [medline]
PHST- 2022/12/06 06:00 [pubmed]
PHST- 2022/12/05 14:12 [entrez]
AID - 10.1080/17474124.2022.2155136 [doi]
PST - ppublish
SO  - Expert Rev Gastroenterol Hepatol. 2023 Jul-Dec;17(8):837-861. doi: 
      10.1080/17474124.2022.2155136. Epub 2022 Dec 26.